<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77391">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112045</url>
  </required_header>
  <id_info>
    <org_study_id>14-X003</org_study_id>
    <nct_id>NCT02112045</nct_id>
  </id_info>
  <brief_title>XM02 Filgrastim to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation</brief_title>
  <official_title>A Study of XM02 Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized study to test the safety and efficacy of the recombinant G-CSF XM-02
      filgrastim (Granix) plus high dose melphalan versus high dose melphalan alone prior to
      autologous stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>CR and sCR</measure>
    <time_frame>100 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR) requires all of the following:
Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine
&lt;5% plasma cells in the bone marrow
Disappearance of soft tissue plasmacytomas
Stringent complete response (sCR) requires all of the following:
CR as defined above
Normal free light chain ratio
Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of XM-02 filgrastim + (High Dose Melphalan) HDM to HDM alone</measure>
    <time_frame>107 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (CR+ sCR) + VGPR + PR</measure>
    <time_frame>2 years 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR), disappearance of monoclonal protein from the blood &amp; urine and &lt;5% plasma cells in bone marrow &amp;disappearance of soft tissue plasmacytomas
Stringent complete response (sCR), CR &amp; normal free light chain ratio &amp; absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence
Very good partial response (VGPR), serum and urine monoclonal protein detectable by immunofixation but not on electrophoresis OR &gt; 90% reduction in serum monoclonal protein with urine monoclonal protein &lt; 100 mg per 24 hours and if present, &gt; 50% reduction in the size of soft tissue plasmacytomas
Partial response (PR), &gt; 50% reduction in the level of the serum monoclonal protein &amp; reduction in urine monoclonal protein &amp; &gt; 50% reduction in the size of soft tissue plasmacytomas &amp; if serum and urine monoclonal protein are unmeasurable and serum free light chain is unmeasurable, a &gt; 50% reduction in plasma cells is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival comparing XOM filgratim + HDM  to HDM alone</measure>
    <time_frame>2 years 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival (OS) is defined as the duration from the time of transplant Day 0 to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression=free survival comparing XOM filgratim + HDM  to HDM alone</measure>
    <time_frame>2 years 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS) is defined as the duration from time of transplant Day 0 to time of first progression/clinical relapse, death, or the date the patient was last known to be in remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil engraftment  comparing XOM filgratim + HDM  to HDM alone</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Neutrophil engraftment is defined as ANC ≥ 0.5 × 109/L × 3 consecutive daily assessments. The first of 3 consecutive days for which ANC ≥ 0.5 × 109/L will be recorded as the date of neutrophil engraftment. Time to neutrophil engraftment will be calculated as the time from the date of the ASCT to the date of neutrophil engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment comparing XOM filgratim + HDM  to HDM alone</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Platelet engraftment is defined as an untransfused platelet measurement &gt;20,000/mm3 × 3 consecutive daily assessments. The first of 3 consecutive days for which the untransfused platelet measurement is &gt;20,000/mm3 will be recorded as the date of platelet engraftment. Time to platelet engraftment will be calculated as the time from receiving the date of ASCT to the date of platelet engraftment.  Untransfused is defined as no transfusions within 7 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>XM02 filgrastim and high dose melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XM02 filgrastim and high dose melphalan</intervention_name>
    <description>XM02 filgrastim 5 mcg/kg on Days -7 through -2 Melphalan 100 mg/m2 on Days -3 through -2</description>
    <arm_group_label>XM02 filgrastim and high dose melphalan</arm_group_label>
    <other_name>Granix</other_name>
    <other_name>Alkeran® Tablets</other_name>
    <other_name>Phenylalanine mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose melphalan</intervention_name>
    <description>Melphalan 100 mg/m2 on Days -3 through -2</description>
    <arm_group_label>High dose melphalan</arm_group_label>
    <other_name>Alkeran® Tablets</other_name>
    <other_name>Phenylalanine mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Stem Cell infusion Day 0</description>
    <arm_group_label>XM02 filgrastim and high dose melphalan</arm_group_label>
    <arm_group_label>High dose melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic multiple myeloma requiring treatment

          -  Received at least two cycles of any regimen as initial systemic therapy for multiple
             myeloma and are within 2-12 months of the first dose of initial therapy

          -  At least 18 years of age

          -  Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved,
             peripheral blood stem cell collection containing at least 2 × 106 CD34+ cells/kg
             based on patient body weight.

          -  Adequate organ function as measured by:

          -  Cardiac function: Left ventricular ejection fraction at rest ≥40%

          -  Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine amino
             transferase (AST/ALT) ≤3 × ULN

          -  Renal function: Creatinine clearance ≥40 mL/minute (measured or calculated/estimated)

          -  Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for
             hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory
             vital capacity (FVC) ≥50% of predicted value

          -  Oxygen saturation ≥92% on room air

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document

        Exclusion Criteria:

          -  Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior
             to ASCT

          -  Prior stem cell transplant (autologous or allogeneic)

          -  Smoldering MM not requiring therapy

          -  Plasma cell leukemia

          -  Systemic amyloid light chain amyloidosis

          -  Active bacterial, viral, or fungal infection

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Known, active hepatitis A, B, or C Infection

          -  Pregnant or breastfeeding.

          -  Receiving other concurrent anticancer therapy (including chemotherapy, radiation,
             hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days
             prior to the ASCT or planning to receive any of these treatments prior to the last
             study visit on Day +100.

          -  Hypersensitive or intolerant to any component of the study drug(s) formulation

          -  Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor,
             etc) or undergoing apheresis &lt; 14 days prior to the start of treatment on protocol
             (Day -7).

        Inclusion of Women and Minorities

        -Both men and women and members of all races and ethnic groups are eligible for this
        trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Vij, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ravi Vij, M.D.</last_name>
    <phone>314-454-8304</phone>
    <email>rvij@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravi Vij, M.D.</last_name>
      <phone>314-454-8304</phone>
      <email>rvij@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Camille Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Christopher, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meagan Jacoby, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rizwan Romee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Schroeder, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Stockerl-Goldstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micheal Tomasson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Uy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Walter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas Wartman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Welch, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Westervelt, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
